Intro

This chapter explores the management of refractory distributive shock with a focus on the innovative treatment angiotensin 2, or GIAPREZA. It examines the epidemiology of distributive shock, particularly emphasizing sepsis, and discusses the complexities and challenges of critical care management in ICU settings.